Empagliflozin to Prevent Worsening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction (EMPRESS-MI)
European Journal of Heart Failure · 01.03.2025 · 27 (3) · 566-576
DOI: 10.1002/ejhf.3560 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, online erschienen am 15.12.2024. Verfasst von Jaclyn Carberry und 24 weiteren Autor:innen. Beteiligte Einrichtung: British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Myocardial Infarction, Sodium-Glucose Transporter 2 Inhibitors, Stroke Volume. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, British Heart Foundation.
Abstract (Originalsprache)
Aims
Patients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are considered to be at risk of progressive adverse cardiac remodelling which can lead to the development of heart failure and death. The early addition of a sodium–glucose cotransporter 2 (SGLT2) inhibitor to standard treatment may delay or prevent progressive adverse remodelling in these patients. Methods and results We performed a randomized, double-blind, placebo-controlled, multicentre trial using cardiovascular magnetic resonance imaging (MRI), in patients with left ventricular systolic dysfunction following MI. Eligible patients were those ≥12 h and ≤14 days following acute MI, with an LVEF <45% by MRI. Patients were randomized to empagliflozin 10 mg once a day or matching placebo. The primary outcome was the change in left ventricular end-systolic volume indexed to body surface area (LVESVI) from baseline to 24 weeks. Secondary outcomes included measures of left ventricular and atrial volumes, left ventricular mass, LVEF, and high-sensitivity troponin I (hs-TnI) and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) concentrations. From October 2022 to January 2024, 105 eligible patients were randomized. The mean age was 63 ± 11 years and 90 (87%) were male. The mean LVEF was 34.8 ± 6.0%. In the placebo group, LVESVI decreased by 7.8 ± 16.3 ml/m2, left ventricular end-diastolic volume index (LVEDVI) did not change (−0.3 ± 18.7 ml/m2) and LVEF increased by 8.5 ± 7.4% at 24 weeks from baseline. Empagliflozin did not affect the change in LVESVI from baseline to 24 weeks (between-group difference = 0.3 ml/m2, 95% confidence interval −5.2 to 5.8; p = 0.92). Compared with placebo, empagliflozin also had no effect on LVEDVI, LVEF, left atrial volume index, left ventricular mass index, NT-proBNP, or hs-TnI, but did increase haematocrit and reduced uric acid and weight.
Conclusions
In patients with left ventricular systolic dysfunction after an acute MI receiving contemporary standard of care, treatment with empagliflozin had no effect on cardiac volumes or LVEF compared with placebo. Progressive adverse cardiac remodelling did not occur in the majority of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
- Golden Jubilee National Hospital, Clydebank, UK.
- Robertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
- West of Scotland Innovation Hub, National Health Service Scotland, Glasgow, UK.
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Förderung
- Boehringer Ingelheim
- British Heart Foundation
Zitieren
APA
Carberry, J., Petrie, M. C., Lee, M. M. Y., Stanley, B., Brooksbank, K. J. M., Campbell, R. T., Good, R., Jhund, P. S., Kellman, P., Lang, N. N., Lindsay, M. M., Mangion, K., Gardner, R. S., Mark, P. B., Meyer, B., O'Donnell, J., Orchard, V., Shaukat, A., Watkins, S., …, & Docherty, K. F. (2025). Empagliflozin to Prevent Worsening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction (EMPRESS-MI). European Journal of Heart Failure, 27(3), 566-576. https://doi.org/10.1002/ejhf.3560
Vancouver
Carberry J, Petrie MC, Lee MMY, Stanley B, Brooksbank KJM, Campbell RT, et al. Empagliflozin to Prevent Worsening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction (EMPRESS-MI). European Journal of Heart Failure. 2025;27(3):566-576. doi:10.1002/ejhf.3560
BibTeX
@article{Carberry2025,
author = {Carberry, Jaclyn and Petrie, Mark C and Lee, Matthew M Y and Stanley, Bethany and Brooksbank, Katriona J M and Campbell, Ross T and Good, Richard and Jhund, Pardeep S and Kellman, Peter and Lang, Ninian N and Lindsay, M Mitchell and Mangion, Kenneth and Gardner, Roy S and Mark, Patrick B and Meyer, Barbara and O'Donnell, Joanne and Orchard, Vanessa and Shaukat, Aadil and Watkins, Stuart and McConnachie, Alex and McMurray, John J V and Welsh, Paul and Sattar, Naveed and Berry, Colin and Docherty, Kieran F},
title = {Empagliflozin to Prevent Worsening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction (EMPRESS-MI)},
journal = {European Journal of Heart Failure},
year = {2025},
volume = {27},
number = {3},
pages = {566--576},
doi = {10.1002/ejhf.3560}
}
EUVIMED